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Several genes encoding for proteins involved in prolifer-
ation, invasion, and apoptosis are known to be direct
miR-34a targets. Here, we used proteomics to screen for
targets of miR-34a in neuroblastoma (NBL), a childhood
cancer that originates from precursor cells of the sympa-
thetic nervous system. We examined the effect of miR-34a
overexpression using a tetracycline inducible system in
two NBL cell lines (SHEP and SH-SY5Y) at early time
points of expression (6, 12, and 24 h). Proteome analysis
using post-metabolic labeling led to the identification of
2,082 proteins, and among these 186 were regulated (112
proteins down-regulated and 74 up-regulated). Prediction
of miR-34a targets via bioinformatics showed that 32 tran-
scripts held miR-34a seed sequences in their 3-UTR. By
combining the proteomics data with Kaplan Meier gene-
expression studies, we identified seven new gene prod-
ucts (ALG13, TIMM13, TGM2, ABCF2, CTCF, Ki67, and
LYAR) that were correlated with worse clinical outcomes.
These were further validated in vitro by 3-UTR seed se-
quence regulation. In addition, Michigan Molecular Inter-
actions searches indicated that together these proteins
affect signaling pathways that regulate cell cycle and pro-
liferation, focal adhesions, and other cellular properties
that overall enhance tumor progression (including signal-
ing pathways such as TGF-, WNT, MAPK, and FAK). In
conclusion, proteome analysis has here identified early
targets of miR-34a with relevance to NBL tumorigenesis.
Along with the results of previous studies, our data
strongly suggest miR-34a as a useful tool for improving
the chance of therapeutic success with NBL. Molecular
& Cellular Proteomics 13: 10.1074/mcp.M113.035808,
2114–2131, 2014.
Pediatric neuroblastoma (NBL)1 is the most common ex-
tracranial solid childhood tumor. It is responsible for 15% of
all childhood cancer mortality, with an incidence of 1 to 5 per
million children per year. NBLs originate from immature sym-
pathetic nervous system cells, and almost all NBLs (90%) are
diagnosed in patients younger than 5 years, with the median
age of occurrence being around 22 months (1). The vast
majority of NBLs arise sporadically, although some familial
cases are described. Most of the tumors are found in the
abdomen (65%), often in the adrenal medulla, or elsewhere in
the body where sympathetic nervous system components are
present (2). NBLs are divided into different stages according
to the localization and extension of the primary tumor and the
absence or presence of distant metastases, taking into ac-
count the extent of disease at diagnosis and risk factors
including stages that are defined through imaging (see the
International Neuroblastoma Risk Grouping Staging System
(3, 4)). The clinically heterogeneous nature of NBL partly
arises from its biological and genetic heterogeneity. More-
over, genetic and molecular findings are now routinely con-
sidered in therapeutic decision making (5–9). Amplification of
the MYCN gene and a complex set of chromosomal aberra-
tions are characteristic of poor NBL prognosis, including 1p36
deletion, 11q deletion, and 17q gain (10–12).
MiRNAs are non-coding, single-stranded RNAs of approx-
imately 22 nucleotides, and they constitute a novel class of
gene regulators in both plants and animals. They negatively
regulate their targets in one of two ways, depending on the
degree of complementarity between the miRNA and the tar-
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get. MiRNAs exert their regulatory effects through binding
with canonical 8-mer complementary sites, called “seeds,”
within the 3 untranslated regions (UTRs) of their mRNA tar-
gets. Ebner and Selbach reported additional evidence of seed
recognition sites. Studying miR-34a and miR-34c that shared
the same seed sequence, they were able to identify a distinct
subset of targets (13). These findings enhance the complexity
of the miRNA/target regulation.
Other reports have defined different post-transcriptional
repression mechanisms in which miRNAs use their central
region to pair to their targets or in which miRNAs can simul-
taneously bind 5-UTR and 3-UTR motifs through their 3-
and 5-end sequences, respectively, to drive mRNA cleavage
(14, 15). In general, the translational control mechanism used
by miRNAs to reduce the protein levels of their target genes
implies that the mRNA levels of these genes might be affected
(16, 17).
MiR-34a was reported in prostate carcinomas and in pri-
mary melanomas, as well as in several tumor cell lines (18),
and its loss has been linked to chemoresistance of cancers.
Several studies have reported that the three miR-34 family
members that have been identified are direct targets of p53,
and their ectopic expression can reproduce p53-mediated
effects, including cell-cycle arrest and induction of apoptosis
and senescence-like phenotypes, whereas inhibition of miR-
34a functions impairs p53-induced apoptosis upon DNA
damage induction (19). Ji and colleagues (20) have shown
another potential role for miR-34 in cancer initiation and pro-
gression in human pancreatic cancer cells, linked to its func-
tion to counteract the maintenance of tumor-initiating cells.
Another study demonstrated that in CD44-positive prostate
cancer cell populations (compared with CD44-negative cells),
miR-34a (1p36.22) was prominently underexpressed,
whereas the other two miR-34 family members studied, miR-
34b and miR-34c (11q23.1) (21), did not show consistent
differences between both types of cells. Finally, Guessous
and colleagues (22) have shown that miR-34a expression
reduces glioma stemness and induces cell differentiation into
astrocytes, neurons, and oligodendrocytes. Emerging evi-
dence suggests a role for aberrant miRNA regulation in NBLs.
Expression profiling of miRNAs identified miR-34a at 1p36
and miR-125b at 11q24 as frequently deleted tumor suppres-
sors in NBL. To date, several miR-34a targets have been
experimentally validated, including CDK4/6, cyclin E2, cyclin
D1, E2F5, MET, Bcl2, MYCN, and SIRT1 (23–25).
Although extensive studies have been performed to explore
the role of miR-34a in several cellular frameworks, little is
known about the relationships between the expression of
miR-34a and the down-regulation of its targets at the early
stages of its expression. Here we present a global analysis of
the early effects of miR-34a on protein expression. Using
quantitative bottom-up proteome analysis, we identified sev-
eral new miR-34a targets. This study defined the complex
protein network that is regulated by miR-34a in NBL and the
effects that result from its perturbation in a cellular model
system. Interestingly, integrated analysis of new identified
targets, together with their expression levels in NBL patients,
revealed their importance for correlation with unfavorable out-
comes, thus suggesting the importance of the early action of
miR-34a to control these gene targets and impair NBL pro-
gression. We demonstrate that miR-34a can simultaneously
target the components of several signaling cascades involved
in NBL tumorigenesis and thus the magnitude of miR-34a
effects on protein expression changes that occur at early time
points in NBL cells.
MATERIALS AND METHODS
Cell Culture—Neuroblastoma cell lines SHEP and SH-SY5Y were
grown in RPMI medium containing 10% fetal bovine serum, 2 mM
L-glutamine, and 1% penicillin/streptomycin. Cells were transfected
with the pcDNA™6/TR plasmid, which encodes the Tet repressor,
using Lipofectamine2000 (Invitrogen, Carlsbad, CA). Cellular clones
were generated via selection with blasticidin (5 g/ml) for 10 days to
stabilize the Tet repressor. Positive clones were further transfected
and stabilized with the pT-REx-DEST empty vector, pT-REx-DEST
encoding miR-34a, and pT-REx-DEST encoding sequence-unrelated
control (UNR).
Cellular inducible clones for miR-34a empty vector and UNR were
generated via selection with neomycin (500 g/ml). Tr6/pT-REx-DEST
miR-34a, Tr6/pT-REx-DEST empty vector, and Tr6/pT-REx-DEST
UNR clones were grown in RPMI medium supplemented with blasti-
cidin (5 g/ml) and neomycin (500 g/ml).
Tr6/pT-REx-DEST miR-34a and Tr6/pT-REx-DEST UNR positive
cell clones were evaluated by Real Time 12 h after the addition of
tetracycline to a final concentration of 2 g/ml. Further details are
provided in the supplemental material.
RNA Extraction and Quantitative Real-time PCR—Total RNA was
extracted from cells using Trizol (Invitrogen) according to the man-
ufacturer’s instructions, and this extract was treated with RNase-free
DNase (Promega, Madison, WI). Total RNA (1 g) was reverse tran-
scribed using the iScriptTM cDNA Synthesis Kit (Bio-Rad, Laborato-
ries, Inc. 2000, Hercules, CA). The reverse transcription products
(cDNA) were amplified via real-time quantitative PCR using a 7900
Real-Time PCR System (Applied Biosystems, Carlsbad, CA) with
Power SYBR green Master Mix.
For SYBR green PCR, Ct values were normalized to U6. Relative
expressions of target genes were determined via the 2–Ct method.
Data are presented as means  S.E. of two to three replicate
experiments.
Western Blotting—The cells were washed in cold phosphate-buff-
ered saline and lysed in protein lysis buffer (20 mM sodium phosphate,
pH 7.4, 150 mM NaCl, 10% glycerol, 1% Na-deoxycholate, and 1%
Triton X-100) supplemented with protease inhibitors (Roche, Diag-
nostics, Mannheim, Germany). Cell lysates (50 g) were separated on
10% SDS-PAGE gels and transferred onto PVDF membranes (Milli-
pore, Corporation, Billerica, MA). After 1 h of blocking with 5% dry
milk fat in phosphate-buffered saline containing 0.02% Tween-20, the
membranes were incubated with the primary antibody overnight at
4 °C, and then with the secondary antibody for 1 h at room temper-
ature. The bands were visualized with a chemiluminescence detection
system (Pierce, Rockford, lL) according to the manufacturer’s instruc-
tions. Information on the antibody used and a description of the
experimental procedure are presented in the supplemental material.
Proteome Analysis—To analyze the effect of miR-34a on protein
levels, we used post-metabolic peptide labeling with NHS esters of
either 12C3 (empty vector, control cells) or
13C3 (miR-34a expressing
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cells) propionate (26). In brief, samples derived from three indepen-
dent doxycycline (DOX) treatments of the same clone were lysed as
previously described (27) and pooled together. Then, we desalted
each sample by loading 1 ml of sample on a NAPTM-5 column (GE
Healthcare), induced digestion by adding trypsin in a trypsin/protein
ratio of 1/500, and incubated the samples overnight at 37 °C. The
peptides were labeled post-metabolically using 20 mM N-hydroxy-
succinimide propionate esters (26). Equal amounts of peptide sample
were mixed and fractionated via RP-HPLC as described previously
(27). Following peptide fractionation, peptide fractions eluting 20 min
apart were pooled to reduce the number of high-performance LC-
MS/MS runs (20 per analysis). Peptides were then analyzed on an
LTQ-Orbitrap Velos mass spectrometer.
The obtained peptide mixtures were introduced into an LC-MS/MS
system, an Ultimate 3000 RSLC nano (Dionex, Amsterdam, The Neth-
erlands) in-line connected to an LTQ Orbitrap Velos (Thermo Fisher
Scientific, Bremen, Germany), for analysis. Peptides were loaded on
a trapping column (made in-house; 100 m inner diameter  20 mm,
5-m beads, C18 Reprosil-HD, Dr. Maisch). After being back-flushed
from the trapping column, the sample was loaded on a reverse-phase
column (made in-house; 75 m inner diameter  150 mm, 3-m
beads, C18 Reprosil-HD, Dr. Maisch, Ammerbuch-Entringen, Ger-
many). Peptides were loaded with solvent A (0.1% trifluoroacetic acid,
2% acetonitrile) and were separated with a linear gradient from 2%
solvent A (0.1% formic acid) to 55% solvent B (0.1% formic acid,
80% acetonitrile) at a flow rate of 300 nl/min, followed by a wash
reaching 100% solvent B.
The mass spectrometer was operated in data-dependent mode,
automatically switching between MS and MS/MS acquisition for the
10 most abundant peaks in a given MS spectrum. In the LTQ-Orbitrap
Velos, full-scan MS spectra were acquired in the Orbitrap at a target
value of 1E6 with a resolution of 60,000. The 10 most intense ions
were then isolated for fragmentation in the linear ion trap, with a
dynamic exclusion of 30 s. Peptides were fragmented after filling the
ion trap at a target value of 1E4 ion counts. From the MS/MS data in
each LC run, Mascot Generic Files were created using Distiller soft-
ware (version 2.4.3.3, Matrix Science, Inc, Boston, MA). In the gen-
eration of these peak lists, grouping of spectra was allowed in Distiller
with a maximum intermediate retention time of 30 s, and a maximum
intermediate scan count of 5 was used where possible. Grouping was
done with a 0.005-Da precursor tolerance. A peak list was only
generated when the MS/MS spectrum contained more than 10 peaks.
There was no deisotoping, and the relative signal-to-noise limit was
set at 2. These peak lists were then searched with the Mascot search
engine (28) using the Mascot Daemon interface (version 2.4, Matrix
Science). Spectra were searched against the Swiss-Prot database
(version 20111214, sequence number 533657). Variable modifica-
tions allowed were pyro-glutamate formation of N-terminal glutamine
and acetylation of the N terminus. Methionine oxidation was set as a
fixed modification. The mass tolerance on precursor ions was 10 ppm
(with Mascot’s C13 option set to 1), and that on fragment ions was 0.5
Da. The peptide charge was set at 1, 2, 3, and the instrument
setting was electrospray ionization–TRAP. The enzyme was set to
endoproteinase Lys-C, allowing one missed cleavage; also, cleavage
was allowed when lysine was followed by proline. Only peptides that
were ranked 1 and scored above the threshold score, set at 99%
confidence, were withheld. The false discovery rate was calculated
for every search and was always found to be lower than 1.5% (see
supplemental Table S1).
Identified peptides were quantified using Mascot Distiller Toolbox
version 2.4.0 (Matrix Science) in the precursor mode. All data man-
agement was done by ms lims (29). The results of analyses are
shown as the peptide ratio of the light (L)-labeled (empty vector, 12C3)
versus the heavy (H)-labeled sample (miR-34a, 13C3). Data analysis
was performed using R embedded in Knime. The data were filtered by
removing all peptides smaller than eight amino acids, and only the
proteins containing at least two peptides were taken into account for
data analysis. The data are available in the PRIDE database (30). The
data were converted using PRIDE Converter (31).
MiR-34a Target Prediction—MiR-34a targets were predicted based
on examinations of predicted targets from TargetScan, miRanda, and
Probability of Interaction by Target Accessibility (PITA). Each data-
base relies on different algorithms of target prediction and uses
different read-out scales. Potential gene targets were chosen based
on their presence in at least two of the databases of all of the
predicted algorithms used in the analysis.
Cloning of 3-UTRs—The 3-UTRs of selected mRNAs containing
putative miR-34a binding sites were PCR-amplified from human
genomic DNA with the Kapa HiFi HotStart system (Kapa Biosystem,
Woburn, MA). These 3-UTRs were cloned into pRL-TK vector (Pro-
mega) and verified by sequencing. A detailed list of 3-UTRs, their
sequences, and primers used for cloning is provided in the supple-
mental material.
Luciferase Assays—HEK293 cells were seeded in 12-well format
and transfected after 24 h with 100 ng of the indicated Renilla lucif-
erase reporter plasmid, 20 ng of Firefly reporter plasmid as a normal-
ization control, and 50 ng of miR-34a or a negative control oligonu-
cleotide. Luciferase assays were carried out 24 h after transfection
using the Dual Luciferase Reporter assay system (Promega) accord-
ing to the manufacturer’s instructions. Fluorescence intensities were
measured with a luminometer (Stratec, Birkenfeld, Germany).
Protein Stability Assay—SHEP and SH-SY5Y cells grown in RPMI
1640 medium supplemented with 10% fetal calf serum were seeded
on six-well plates and treated with 20 g/ml cycloheximide in di-
methyl sulfoxide or dimethyl sulfoxide alone for various times. Cellular
extracts were prepared in lysis buffer consisting of 20 mM sodium
phosphate, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Na-deoxy-
cholate, and 1% Triton X-100 supplemented with protease inhibitors
(Roche). Then 25 g of the protein extract was resolved on
SDS-PAGE, and immmunoblotting was carried out using standard
protocols with anti-ABCF2, anti-TGM2, anti-LYAR, anti-ALG13, anti-
TIMM13 (Abcam, Cambridge, UK), -tubulin (Sigma-Aldrich, Buchs,
SG, Switzerland), and anti-mouse IgG-HRP (Zymed Laboratories Inc.,
S San Francisco, CA). Quantification of the bands was done using
ImageJ.
Adhesion Assay—The SHEP and SH-SY5Y cells were washed with
1 mg/ml BSA in RPMI and blocked for 1 h with 5 mg/ml BSA in RPMI
at 37 °C. Then the cells (5  104 cells) were added to 96-well plates
previously coated (16 h at 4 °C) with 10 g/ml fibronectin (BD Bio-
sciences), 10 g/ml mouse collagen IV (BD Biosciences), or 1 g/ml
BSA. The cells were allowed to adhere for 1 h after treatment with 2
g/ml doxycycline for 3 h to induce endogenous miR-34a expression.
The cells were washed carefully, fixed, stained with crystal violet,
dried overnight, and lysed in 2% SDS. Cell numbers were estimated
with a SpectraMax microplate reader (Molecular Devices, Sunnyvale,
CA) at 550 nm. The background absorbance from a BSA-coated well
was subtracted. Statistical significance was determined using St-
udent’s t tests.
Statistical Analyses—All biochemical experiments were performed
in triplicate unless otherwise stated. The two-tailed Student’s t test
was used to test for significance. Survival curves were constructed
via the Kaplan and Meier method, with differences between curves
tested for statistical significance using the log-rank test.
RESULTS
Conditional miR-34a Expression in Neuroblastoma Cell
Lines—Seed sequence analyses and whole-genome mRNA
sequences stored in public databases predict that miR-34a
miR-34a Targets in NBL
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might have many more targets than those already identified
(32–34). In order to identify miR-34a targets, we generated
several cellular stable clones containing tetracycline-inducible
precursor miR-34a in two different NBL cell lines, SHEP and
SH-SY5Y. We chose these two cellular models because al-
though they originate from the same parental cell line (SK-N-
SH), they show different biological features, being epithelial
and neuroblast-like cells, respectively (35). The system used
here minimized the variability of microRNA expression upon
transient transfection and, during microRNA processing, re-
duced the side effects on RNA-induced silencing complex
obstruction, a phenomenon that occurs if a miRNA is consti-
tutively expressed. Ectopic expression of pre-miR-34a and
mature miR-34a in each generated clone was verified via
RT-PCR (supplemental Figs. S1A and S1B). Here, we de-
tected in some clones a significant (p  0.05) fold increase of
mature miR-34a levels in tetracycline-treated cells 6 h after
induction relative to untreated control cells (supplemental
Figs. S1A and S1B). From among the clones analyzed, we
chose SHEP-D and SH-SY5Y-4 for further experiments, as
both clones showed low levels of endogenous miR-34a and
comparable levels of miR-34a expression upon DOX stimula-
tion.
To further evaluate the responsiveness to DOX as a function
of time, we evaluated miR-34a expression in a time-depen-
dent manner in SH-SY5Y-4 cells. DOX promoted a rapid
increase in pre-miR-34a expression (supplemental Fig. S1C),
with about 10-fold higher levels of pre-miR-34a after 1 h of
DOX treatment, and pre-miR-34a expression increased fur-
ther after 4 h of DOX treatment (approximately 15-fold). As
expected, the expression of mature miR-34a followed similar
kinetics as pre-miR-34, showing higher levels after 1 h of
induction, thus suggesting that pre-miR-34a processing hap-
pens quickly (supplemental Figs. S1C and S1D). Further, we
evaluated miR-34a levels at later time points (supplemental
Figs. S1E and S1F) and verified the protein levels of previously
studied miR-34a targets (Survivin, Cyclin D3, and C-MYC; see
Ref. 32), thus confirming their specific decreased levels fol-
lowing 48 h of induction of miR-34a expression (supplemental
Figs. S1G and S1H). Having validated miR-34a expression
and its effects on known late targets, we employed these cells
for differential proteome analysis (Fig. 1).
Early Time Point miR-34a-induced Proteome Changes—
SHEP-D and SH-SY5Y-4 clones and their respective controls
(empty vector inducible clones) were stimulated with DOX,
and cells were harvested 6, 12, or 24 h after induction. Sub-
sequently, protein samples were prepared and subjected to
mass spectrometric analysis (performed in biological dupli-
cate). In total, over 3,500 proteins were identified by at least
two different peptides (supplemental Fig. S2A). To identify
early miR-34a targets, we focused on differentially expressed
proteins 6 h after DOX induction in both NBL cell lines (protein
ratio distributions are shown in supplemental Fig. S2B). Each
time point of proteomic analyses was the result of a pool (in
equal molar ratio) of three independent DOX induction exper-
iments for each clone in the analysis. Given that the proteomic
fluxes introduced by miRNAs are often subtle, unlike many
other studies that report, for instance, the top quartile of
regulated proteins, we decided to use a statistical approach
that, within each individual experiment, identified those pro-
teins with significantly altered protein levels (p  0.01). In this
way, in SHEP-D and SH-SY5Y-4 cells, 12 and 21 proteins,
respectively, were found to be up-regulated, whereas 20
down-regulated proteins were found in SHEP-D cells, and 56
in SH-SY5Y-4 cells (Fig. 2A). Of note, only five proteins
(COL1A1, PLEC, PTRF, VIME, and RRMJ3) were common
among the down-regulated proteins in both cell lines, and
when this analysis was repeated for samples after 12 h of
miR-34a induction, only one common protein was identified
(COL1A1) (Fig. 2B). This suggests that the repertoire of miR-
34a-affected proteins might be different in the two NBL cel-
lular models studied.
Great attention is given today to miRNA targets that con-
tain a perfect match to the miRNA seed region in their
3-UTR. We speculated that genes encoding for the five
common proteins down-regulated upon miR-34a expres-
sion had a high probability of being direct miR-34a targets.
To determine whether these proteins were direct targets of
miR-34a, we searched the seed sequences for the match
with miR-34a in the 3-UTR of these transcripts. Using
Probability of Interaction by Target Accessibility, a bioinfor-
matics microRNA target prediction tool, we found that miR-
34a can potentially target plectin (a protein involved in cy-
toskeleton structure and remodeling), polymerase I and
transcript release factor (a protein that enables the dissoci-
ation of paused ternary polymerase I transcription com-
plexes from the 3-end of pre-rRNA transcripts and is re-
quired for dissociation of the ternary transcription complex),
rRNA methyltransferase 3, and vimentin (a protein involved
in epithelial mesenchymal transition).
This analysis was negative for the CO1A1 gene, and any
seed sequence match for miR-34a on the CO1A1 3-UTR
sequence was found. To this end, other efforts were made to
search these sequences within the 5-UTR region and in the
whole coding sequence of CO1A1. These analyses were neg-
ative for the 5-UTR, but several putative seed sites for coding
sequence were identified (G	-10; of note, the value was
above the constrained criterion used in the skim presented in
Fig. 1) (supplemental Fig. S3A). Then, to confirm further the
proteomic data, Western blot analyses were performed on
miR-34a clones and their respective controls upon DOX treat-
ment. The results presented in supplemental Fig. S3B show
that COL1A1 protein was down-regulated in those clones
expressing miR-34a, whereas its levels did not change in
empty vector and UNR clones, thus further suggesting that
miR-34a might regulate COL1A1 protein expression by tar-
geting seed sequences within its coding sequence. At this
miR-34a Targets in NBL
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time we cannot exclude the action of other, indirect mecha-
nisms that might regulate COL1A1 expression.
We then tested whether regulation by miR-34a was a direct
effect of miR-34a on seed recognition in the 3-UTR of each
transcript. For this the full-length 3-UTR of each gene was
cloned downstream of a luciferase reporter plasmid. The re-
sulting reporter vectors were transfected into HEK293 cells
together with miR-34a or an UNR, and a dual luciferase re-
porter assay was performed. As shown in supplemental Fig.
S3C, miR-34a repressed the 3-UTR of polymerase I and
transcript release factor and vimentin, whereas it had no
effect on plectin and rRNA methyltransferase 3-UTR lucifer-
ase activities. Taken together, these data show that miR-34a
was able to directly target the 3-UTRs of polymerase I and
transcript release factor and vimentin. This appears to have
led to early down-regulation of the encoded proteins in both
of these NBL models, the SHEP-#D and SH-SY5Y-#4 clones,
which thus shows signaling and functionality of miR-34a
within epithelial mesenchymal transition and RNA transcrip-
tional regulation. However, plectin and rRNA methyltrans-
ferase 3 showed no 3-UTR-mediated down-regulation fol-
lowing the miR-34a expression, leading us to speculate that
there are probably other mechanisms of silencing that are not
yet known but which need to be considered and which could
be revealed by mass spectrometry analysis.
We then investigated the effects of pre-miR-34a expression
on the proteome at later time points (i.e. 12 h after the induc-
tion of pre-miR-34a expression). As shown in Fig. 2B, there
FIG. 1. Schematic outline of post-
metabolic labeling with NHS-propio-
nylate (C12 and C13) on lysine (K) and
arginine (R) residues coupled with
mass spectrometry analysis. SHEP
and SH-SY5Y inducible clones were
stimulated with doxycycline to activate
pre-miR-34a expression and harvested
at three different time points (6, 12, and
24 h). After labeling, samples were
mixed together in a 1:1 ratio and frac-
tionated via RP-HPLC. Bottom, repre-
sentative workflow showing the path fol-
lowed in this study.
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were 26 and 23 significantly down-regulated proteins in the
SHEP-D and SH-SY5Y-4 clones, respectively. Among these,
only one was common to both the SHEP-D and SH-SY5Y-4
clones: COL1A1, which was already found to be down-regu-
lated upon 6 h of miR-34a expression.
Global gene ontology analyses showed that although the
two cell lines had different characteristics, the repertoire of
miR-34a-affected proteins had similar biological functions
(see supplemental Table S5) and were implicated in metabolic
processes, cellular component assembly, cytoskeleton reor-
ganization, biological regulation, and apoptosis, among other
functions. Furthermore, we saw that the down-regulated pro-
teins identified in both cellular models were involved in several
common pathways (supplemental Figs. S4A and S4B).
Although it is known that mRNAs are down-regulated by
miRNAs, little is known about any potential up-regulation
processes involving those mRNAs. Tsai and colleagues (36)
showed that miR-346 can up-regulate the expression of its
FIG. 2. Venn diagrams of down-regulated proteins identified in SHEP and SH-SY5Y cells 6 h (A) and 12 h (B) after miR-34a induction.
Tables show the list of the overlapping proteins in SHEP and SH-SY5Y cells and the log2 ratio (peptide ratio of the light (L)-labeled (empty
vector, 12C3) versus the heavy (H)-labeled sample (miR-34a,
13C3) of each protein at each time point. C, 186 proteins were found to be regulated
by miR-34a in SHEP and SH-SY5Y cells. Among them, 74 were up-regulated and 112 were down-regulated. D, schematic representation of
proteins regulated between different time points in the same cell line. Green indicates increased protein amount, black represents no change,
and red denotes down-regulated proteins (normalized Log2 values).
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targets. This is investigated in Fig. 2C, which illustrates all of
the protein expression changes (up- and down-regulation)
arising from the induction of pre-miR-34a expression at 6 h,
12 h, and 24 h. The highlights illustrated in the magnified
insets in Fig. 2D show the proteins for which the down-
regulation was constant at each time point and the proteins
whose amounts fluctuated over the 24 h of induction of miR-
34a expression.
Having established that several proteins were found to be
regulated at early time points, we investigated when and how
these effects occurred.
In Fig. 3, we present the relationship between miR34a-
induced fold changes in protein expression at two different
time points (6 h versus 12 h, 6 h versus 24 h, or 12 h versus
24 h). The results show that the correlation (Pearson’s coef-
ficient values) between protein fold changes decreased when
we plotted 6 h versus 12 h and 6 h versus 24 h in both cell lines
analyzed, indicating that the majority of the miR34-a effect
occurs at early time points.
The approach presented here is different from previously
used models (21–23) reported in the literature in which pro-
teome variations were measured 24 h or more after miRNA
expression.
Biological Analysis of miR-34a Target Down-regulation and
Functional Impact in Neuroblastoma Cells—Several studies
have shown that in many cell lines, miR-34a suppresses cell
growth by targeting genes involved in G1/S transition through
the induction of a caspase-dependent apoptotic pathway
(17–24, 37–41). For a more detailed analysis, we further eval-
uated cell proliferation in real time using the xCELLigence
system and observed that upon miR-34a induction, cell pro-
liferation of both SHEP-D and SH-SY5Y-4 cells decreased
FIG. 3. Scatter plots correlating changes in protein expression at two different time points as measured via shotgun analysis. A,
normalized log2 ratio at 6 h versus normalized log2 ratio at 12 h. B, normalized log2 ratio at 6 h versus normalized log2 ratio at 24 h. C,
normalized log 2 ratio at 12 h versus normalized log2 ratio at 24 h in SHEP cells. D, normalized log2 ratio at 6 h versus normalized log2 ratio
at 12 h. E, normalized log2 ratio at 6 h versus normalized log2 ratio at 24 h. F, normalized log2 ratio at 12 h versus normalized log2 ratio at 24 h
in SH-SY5Y cells.
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after only 3 h of miR-34a induction (Fig. 4A). To further vali-
date our results, we additionally generated tetracycline-induc-
ible clones of the two NBL cell lines that expressed a non-
silencing RNA (the UNR) (see supplemental Figs. S4C and
S4D). This sequence retained a backbone based on the pre-
miR30 stem and loop (see supplemental material). As shown
in Fig. 4A, upon DOX induction of these UNR-expressing
clones, we did not observe cell proliferation impairment sim-
ilar to the results presented for the empty vector clones.
These generated clones served as controls and confirmed
that the inhibition of proliferation observed upon induction of
miR34a was not due to a nonspecific response to cellular
stress.
To further corroborate these findings, we screened for po-
tential cell cycle alterations in the NBL generated clones via
FACS analysis. We treated asynchronous SHEP and SH-
SY5Y cells with DOX and determined the number of cells in
S-phase, G1-phase, and G2-phase and found a decrease of
cells in the S-phase (57.64% to 34.25% and 52.83% to
35.15%, respectively) and an enhancement of cells in both G1
(40.89% to 53.55% and 46.12% to 55.12%) and G2 phases
(1.47% to 12.20% and 1.06% to 9.73%) relative to the empty
vector clones upon 6 h of miR-34a induction (Fig. 4B). The
UNR clones showed similar results (data not shown).
We additionally found a decrease of cells in the S-phase
and an increase of cells in G1 and G2 phases in miR-34a
overexpressing cells relative to empty vector cells; those re-
sults were similarly observed after 12 h (Fig. 4C) and 24 h (see
supplemental Fig. S4E) of DOX treatment.
Next, we asked whether miR-34a at this early time point of
expression increased the fraction of apoptotic cells by ana-
lyzing for annexin V and propidium iodide staining, but we
found no substantial variation in the fraction of apoptotic cells
in miR-34a-expressing clones, either SHEP or SH-5YSY cells,
relative to control clones. The fraction of annexin V–positive
SHEP cells varied from 2.8% to 3.3%, and that for SH-5YSY
cells varied from 0.6% to 0.3% (Fig. 4D). These results sug-
gest that apoptotic events do not occur substantially in the
early phases of miR-34a expression, but cells undergoing
apoptosis will presumably be present, albeit at the later
stages, after 12 h of miR34a expression.
Selection of Candidate Proteins with Relevance to NBL—
Considering that the genes directly regulated by miRNA might
vary among cell types, we combined proteomics results gen-
erated at 6 and 12 h following miR-34a induction in both cell
lines. In this way, we obtained a set of 112 proteins down-
regulated by miR-34a and thus potentially involved in NBL.
After we sorted this protein set for the presence of miR-34a
seed-matching sequences in the 3-UTRs of their transcripts,
it was predicted that miR-34a could regulate 85/112 proteins
(75.9%). These analyses were performed according to a pre-
viously described method (42) to define the importance of the
evaluation of the energy-based scores for miRNA-target in-
teractions that are equal to the differences between the free
energy gained by the binding of the miRNA to the target (the
G duplex) and the free energy lost by the unpairing of the
target-site nucleotides (the G open). Considering then only
prediction sites with G values 10 (42), we found 32 genes
enriched for an miR-34a seed sequence (Table I). We then
screened these genes/proteins for possible correlation of their
expression levels with clinical outcomes in a public gene-
expression database (R2; GEO I.D.: GSE16476). The aim here
was to improve our target prediction functionality in NBL and,
finally, to explore the potential of those selected genes as
independent predictors of the survival of patients with NBL
(see also Fig. 1). Using this flowchart, we found that among
the genes analyzed, even after using Bonferroni statistical
corrections, of 32 potential miR-34a early targets, only 7
genes significantly correlated with lower overall survival when
they were overexpressed at the mRNA level in NBL tumor
cohorts (n 
 88 cases for mRNAs in this analysis) (see Fig. 5A
and associated table of overall survival). Of note, these genes
were further predicted to retain seed sequences for miR-34a
by two other target-prediction algorithms: TargetScan and
miRanda. These genes are involved in differentiation (LYAR,
CTCF), apoptosis, proliferation (KI67), molecular transport
(TIMM13, ABCF2), and activation of several metabolic path-
ways (TGM2, ALG13).
Given that the most important feature in assessing the validity
of our results was a protein half-life shorter than our experimen-
tal sampling point, we analyzed protein half-lives in our cellular
models. As expected, all proteins evaluated here had a half-life
of less than 3 h (supplemental Figs. S5A and S5B), well below
our earliest proteome sampling time of 6 h of miR-34a expres-
sion. To further validate the mass spectrometry results, we
performed Western blotting and observed down-regulation of
TGM2 and ABCF2 in SHEP-D cells upon 12 h of DOX stimula-
tion (Fig. 5B) and down-regulation of LYAR, CTCF, TIMM13,
and ALG13 in SH-SY5Y-4 cells (Fig. 5C).
Taken together, our data demonstrate that miR-34a, when
ectopically expressed in NBL cells, negatively regulates ad-
ditional genes/proteins that are correlated with poor progno-
sis when overexpressed in NBL.
MiR-34a Regulates a Complex Network of Genes That Are
Involved in Signal Transduction—We next analyzed the sig-
naling pathways that are possibly affected by miR-34a. Pro-
tein network interactions among the proteins identified above
were evaluated using Cytoscape (43). The construction of a
potential “interactome” was achieved by query of LYAR,
CTCF, ALG13, ABCF2, TIMM13, Ki67, and TGM2 to those
reported protein–protein interaction annotated databases
within the Michigan Molecular Interaction database (44). The
Michigan Molecular Interaction plugin allows one to query for
interactions by finding nearest neighbor proteins. Out of the
seven proteins evaluated, five were linked to components of
molecular signaling cascades (LYAR, TGM2, CTCF, TIMM13,
and MKI67). These proteins are mainly involved in cancer
progression and pathways including focal adhesion kinase
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(FAK) signaling, the transforming growth factor  (TGF-)
pathway (45), the MAPK activity signaling pathway, and the
Wnt activation pathway (Fig. 6A).
To validate these findings, we performed dual luciferase
reporter assays. These allowed us to determine whether the
mRNAs of the proteins that are significantly overexpressed in
patients with worse outcomes and down-regulated by miR-
34a in the SHEP-D and SH-SY5Y-4 clones are direct targets
of miR-34a. Four of five genes (CTCF, LYAR, TGM2, and
TIMM13) were significantly repressed when co-transfected with
miR-34a, whereas a control clone using miR-scrambled had no
effect on the luciferase reporter when co-transfected (supple-
mental Fig. S6A). This indicates that there was good correla-
tion between the protein and mRNA levels in our miR-34a-
induced cellular models, and it further supports our scheme
as additional evidence of these bona fide analyses in this
search for new candidates of NBL through the combination of
proteomic analysis in these representative tumorigenic cells
and gene-expression data in patient cohorts.
Proteome studies and luciferase assays did not allow the
determination of the contributions of mRNA destabilization
and translational repression upon miRNA-34a expression. Al-
FIG. 4. A, normalized cell index as a measure of proliferation of SHEP (left, SHEP-D, green line; SHEP-UNR#A, red line; SHEP-UNR#D, blue
line; SHEP-empty vector (E.V.), magenta line) and SH-SY5Y (right, SH-SY5Y-UNR#1, red line; SH-SY5Y-UNR#5, blue line; SH-SY5Y-4, green
line; SH-SY5Y-E.V., magenta line) cells treated with doxycycline (DOX). Data are means  S.D. B, C, propidium-iodide-based FACS analysis
showing that the miR-34a expression 6 h (B) and 12 h (C) after DOX stimulation induced a decrease of SHEP and SH-SY5Y cells in S phase
relative to the control cells. Each resulting histogram consists of three populations: G1 population (to the left, in red), S-phase population (blue
stripe), and G2 population (to the right, in red). D, representative histograms presenting analysis of SHEP and SH-SY5Y inducible clones (12
h after DOX stimulation) stained with annexin V-FITC and propidium iodide (PI). Each dot plot shows four cell populations: heavy damage and
dead cells (square 1) stained very weakly with annexin V-FITC and strongly with PI; secondary necrotic cells (square 2) strongly stained with
PI and annexin V-FITC; viable cells (square 3) weakly stained with PI and annexin V-FITC; and apoptotic cells (square 4) stained strongly with
annexin V-FITC but weakly with PI. All data presented were obtained in triplicate assays and repeated twice.
TABLE I
List of 33 genes enriched for miR-34a seed sequence in their 3-UTR





P19367 HXK1 HK1 6 21.07 SHSY 6H 1.65 0.96
O15231 ZN185 ZNF185 5 16.74 SHEP 6H 3.05 1.45
Q9UG63 ABCF2 ABCF2 7 15.73 SHEP 12H 1.79 0.83
P15586 GNS GNS 5 15.39 SHSY 6H 2.66 1.65
P40261 NNMT NNMT 4 15.31 SHSY 12H 1.99 1.07
Q15746 MYLK MYLK 10 15.13 SHEP 6H 3.29 1.56
P07858 CATB CTSB 9 14.68 SHSY 12H 1.64 0.78
P30419 NMT1 NMT1 12 14.57 SHEP 12H 1.93 0.94
P46013 KI67 MKI67 8 14.46 SHSY 12H 1.79 0.92
Q9UHB6 LIMA1 LIMA1 2 13.68 SHEP 6H 2.55 1.20
Q9UHB6 LIMA1 LIMA1 2 13.68 SHEP 12H 2.34 1.22
P13928 ANXA8 ANXA8 3 13.51 SHSY 12H 2.47 1.38
Q9H307 PININ PNN 2 13.51 SHSY 6H 1.49 0.82
Q9NP73 ALG13 ALG13 1 13.07 SHSY 12H 2.55 1.13
O95340 PAPS2 PAPSS2 6 12.85 SHEP 12H 1.74 0.79
Q8WX93 PALLD PALLD 9 12.72 SHEP 12H 1.96 0.96
P06396 GELS GSN 3 12.71 SHSY 12H 2.55 1.43
P13796 PLSL LCP1 3 12.71 SHSY 12H 4.10 1.71
P21980 TGM2 TGM2 6 12.43 SHEP 12H 2.23 1.15
Q9Y4K1 AIM1 AIM1 5 12.31 SHSY 6H 1.79 1.07
Q13510 ASAH1 ASAH1 2 12.1 SHSY 12H 1.69 0.83
Q96MU7 YTDC1 YTHDC1 5 11.97 SHSY 6H 1.82 0.88
P35659 DEK DEK 2 11.95 SHEP 12H 1.71 0.77
Q6P1J9 CDC73 CDC73 3 11.46 SHSY 12H 181.04 3.95
Q7Z6K5 CO038 C15orf38 6 11.46 SHEP 6H 59.93 3.11
P07339 CATD CTSD 3 11.33 SHSY 12H 2.08 1.14
P09486 SPRC SPARC 5 11.3 SHSY 12H 1.78 0.91
Q9UPN9 TRI33 TRIM33 7 10.97 SHEP 6H 2166.96 6.00
Q9NX58 LYAR LYAR 1 10.66 SHSY 6H 2.32 1.45
P49711 CTCF CTCF 2 10.56 SHSY 6H 1.76 1.05
Q6WKZ4 RFIP1 RAB11FIP1 8 10.39 SHEP 12H 1.72 0.78
Q8WU90 ZC3HF ZC3H15 2 10.28 SHEP 12H 65.84 3.60
Q9Y5L4 TIM13 TIMM13 4 10 SHSY 12H 7.74 2.11
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though some targets were repressed without detectable
changes in mRNA levels (33%), generally the mechanism for
target repression was mRNA destabilization (46). Therefore,
we examined whether miR-34a affected the mRNA stability of
our newly identified targets. To achieve this, we treated con-
trol and miR-34a inducible clones with actinomycin D, which
FIG. 5. A, Kaplan–Meier plots for overall survival based on expression levels of LYAR, CTCF, TGM2, Ki67, TIMM13, ALG13, and ABCF2 in
NBL, with a group separation based on the most significant p value. From among the multiple probe sets corresponding to the same genes,
we chose the probe sets with the highest average present signal (APS, average signal of all samples considered to express a selected gene)
using the program default setting. Next to the Kaplan plot is a small subplot that is a graphical representation of the p value plotted against
the mRNA expression level values. Additional information is reported in the table. B, total proteins prepared from SHEP-UNR, SHEP–empty
vector (E.V.), and SHEP-D treated with DOX for different times (0 h, 6 h, and 12 h) were subjected to Western blotting with anti-TGM2 and
ABCF2 antibodies. -Tubulin was used as the loading control. C, expression levels of LYAR, CTCF, ALG13, and TIMM13 decreased upon DOX
treatment in SH-SY5Y-4 relative to SH-SY5Y-E.V. and SH-SY5Y-UNR. -Tubulin was used as the loading control.
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impairs mRNA transcription (47), and then harvested the cells
at different time points after DOX treatment. As shown in
supplemental Fig. S6B, miR-34a expression enhanced the
degradation of ABCF2, TGM2, LYAR, and CTCF mRNAs,
whereas no effect on mRNA half-life was observed in KI67,
ALG13, TIMM13, or VIMENTIN genes. This indicates that the
latter transcripts are subjected to translational repression.
Collectively, these findings suggest that miR-34a was equally
able to both destabilize mRNAs and repress translational
events of target molecules. These data are in agreement with
those previously reported by Kaller et al. on the SW480 cel-
lular human colorectal cancer cell model (33).
Many of the pathways mentioned above converge on com-
mon downstream effectors that are well-established links to
cancer. To verify down-regulation of the Wnt pathway, we
analyzed expression of activated -catenin in both NBL cells
upon miR-34a expression. As shown in Figs. 6B and 6C,
active -catenin expression was reduced after 6 h of miR-34a
expression in both cell lines, indicating that miR-34a led to
Wnt signaling down-regulation and confirming our predic-
tions. We then analyzed the TGF- pathway, known to regu-
late several cellular functions. After phosphorylation and ac-
tivation of TRI, the transcription factors receptor-activated
Smad2 and Smad3 are recruited and activated through phos-
phorylation of C-terminus residues; this converts them into
transcriptional regulators that complex with Smad4, which
then moves to the nucleus to induce gene transcription. We
found that miR-34a expression in SH-SY5Y-4 cells led to a
significant decrease in Smad2 phosphorylation (Figs. 6B and
6C), indicating that miR-34a also impairs TGF- signaling.
We further analyzed FAK signaling, which is coordinated by
large, integrin-containing multiprotein assemblies spanning
the plasma membrane that link the cellular cytoskeleton to the
extracellular matrix. FAK is a 125-kDa non-receptor tyrosine
kinase that plays a major role in mediating signal transduction
by integrins, as well as by growth factor receptors, and in
regulating cell adhesion, migration, proliferation, and differen-
tiation in a variety of cell types. FAK has also been implicated
in regulating the expression of Snail, Zeb1, Zeb2, and Twist in
fibroblasts (48), and the expression of these transcription
factors is crucial for maintenance of the mesenchymal phe-
notype of murine fibroblasts, including suppression of E-cad-
herin gene expression. We found that the expression of both
FAK and pFAK Tyr397 was suppressed upon miR-34a ex-
pression (Figs. 6B and 6C), which prompted us to investigate
the adhesion capabilities of cells with increased miR-34a
expression. As shown in Fig. 6D and supplemental Fig. S7D,
if miR-34a was not ectopically expressed, the adhesion index
increased significantly (p  0.05); conversely, low levels of
adhesion cellular abilities were evident in both cell lines
(SHEP-D and SH-SY5Y-4).
Thus we have here comprehensively demonstrated the
functional abilities of miR-34a to simultaneously target the
components of known cancer signaling cascades that are
responsible for tumor progression.
DISCUSSION
The identification of miRNA targets that are functionally
important for tumor biology is crucial for understanding
miRNA functions. By directly measuring changes in protein
levels, one can obtain proteome data that are likely to be more
relevant than microarray data on transcripts. Indeed, silencing
by miRNA does not always show correlation between tran-
script and protein levels (49).
Here, we analyzed proteome changes in two different NBL
cell lines: SHEP cells, which are highly substrate adherent and
grow in monolayer cultures but do not form tumors in nude
mice, and SH-SY5Y cells, which have small, rounded cell
bodies with many lamellipodia and neurites extending from
the soma and which are tumorigenic in nude mice. These
phenotypes are signs of less aggressiveness in vivo for SHEP
cells, due to their milder phenotype relative to SH-5YSY cells.
The analyses presented here reveal new direct targets of
miR-34a that presumably represent the mediators of its cu-
mulative effects on cell behavior during its expression. Direct
regulation by miR-34a was confirmed by reporter gene assays
for selected miR-34a target mRNAs, which showed that miR-
34a-mediated repression did not necessarily require the pres-
ence of seed-matching sequences in the respective 3-UTRs.
Among the detected proteins, 186 were significantly regu-
lated, with 112 proteins being down-regulated and 74
up-regulated upon miR-34a expression. Among the down-
regulated proteins, we noted several proteins involved in apo-
ptosis, cell motility, cell division, and metabolic processing.
Some of these proteins do not contain predicted miR-34a
binding sites in the 3-UTRs of their mRNAs. Although we
used a seed-driven approach to predict putative targets, miR-
mediated down-regulation is not necessarily constrained to
this rule (14, 15, 50, 51). MiRs are potentially targeted to other
regions of the mRNA, such as CDS or the 5-UTR. This could
be the case for COL1A1 regulation as discussed above; future
studies should address this specific control of expression by
miR-34a.
FIG. 6. A, interactome of LYAR, TGM2, CTCF, TIMM13, and MKi67 obtained using the MiMI plug-in of the Cytoscape program. B, C, total
protein extracts prepared from UNR, empty vector (E.V.), or -miR-34a of both SHEP (B) and SH-SY5Y (C) cell clones, treated or not with DOX
for 6 h and then subjected to Western blotting to evaluate Wnt, TGF-, and FAK pathway activity. -Actin and -tubulin were used as loading
controls, and in relative protein densitometric analysis, each value was expressed as fold-stimulation over the unstimulated cells (t0). D,
attachment of SH-SY5Y and SHEP cell empty vector (E.V.) or miR-34a overexpressing cells on fibronectin and collagen I. Cells were treated
or not with DOX for 3 h and then plated on wells uncoated or coated with fibronectin or collagen I. Results are shown as the percentage of
adherent cells with respect to adherent empty vector cells. *p 	 0.005, **p 	 0.005, and ***p 	 0.0005.
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We then identified several early targets of miR-34a (Table I)
and, among these, seven proteins (LYAR, CTCF, TGM2, Ki67,
TIMM13, ALG13, and ABCF2) having prognostic relevance in
NBL.
LYAR, a nucleolar protein, encodes a polypeptide consist-
ing of 388 amino acids with a zinc finger motif and three
copies of nuclear localization signals. Literature data show
that LYAR cDNA overexpression in NIH-3T3 fibroblast cells
changes their phenotype to a more tumorigenic one, indicat-
ing that LYAR is a novel nucleolar protein that can be involved
in cell growth regulation (52). Recently, microarray data
showed that LYAR is highly expressed in undifferentiated
human ES cells and significantly down-regulated upon differ-
entiation (53). Thus, LYAR appears to be a likely player in
controlling the self-renewal of ES cells. Li and colleagues (54)
demonstrated that LYAR down-regulation significantly re-
duces the growth rate of ES cells and increases apoptosis.
Moreover, reduced expression of LYAR in ES cells impairs
their differentiation capacity, failing to rapidly silence pluripo-
tency markers and activate differentiation genes upon differ-
entiation. Future studies will be needed to assess the relevant
function of LYAR in NBL tumor cell biology.
We also identified CTCF, which encodes a highly conserved
zinc-finger protein implicated in multiple regulatory functions,
including transcriptional activation/repression, insulation, im-
printing, and X chromosome inactivation. Various studies
have shown that CTCF is involved in cell cycle arrest, apo-
ptosis, and differentiation, indicating that it is a potential tu-
mor-suppressor factor. Other studies, however, found that
CTCF protein levels are elevated in both breast and lung
tumoral cell lines (55, 56) and are also associated with apo-
ptosis resistance (55). These controversial results can be ex-
plained by the role of CTCF as a differentiation-inducing fac-
tor, involving a variety of signaling pathways depending on its
cellular context (57–59).
TGM2 (TG2) encodes the tissue transglutaminase, known
to be an important member of the transglutaminase family of
enzymes that catalyze Ca2-dependent post-translational
modification of proteins. Involvement of TG2 in apoptosis has
been well established, and its overexpression either results in
spontaneous apoptosis of cells or renders cells highly sensi-
tive to apoptosis-inducing agents. In contrast, recent evi-
dence indicates that increased expression of TG2 may
prolong cell survival by preventing apoptosis (60). TG2 ex-
pression is additionally up-regulated in drug-resistant and
metastatic cancer cells and plays a role in the constitutive
activation of NF-B signaling. Increased expression of TG2
contributes to increased survival, invasion, and motility of
breast cancer (61) and colorectal cancer cells (62). Finally, a
recent study demonstrated that TGF--induced TG2 en-
hances ovarian tumor metastasis by inducing epithelial mes-
enchymal transition and a cancer stem cell phenotype (63).
ABCF2 encodes a member of the ATP binding cassette
transporter family. These act as efflux pumps and are related
to chemoresistance. ABCF2 has a chromosome gain at 7q
34–36. ABCF2 overexpression was found in a chemoresistant
clear-cell ovarian carcinoma and it was suggested that
ABCF2 might contribute to the chemoresistant phenotype in
other tumors as well (64). Moreover, the ABCF2 protein might
be a prognostic marker for clear-cell ovarian adenocarcinoma
(65). As shown in Fig. 5A, gene expression data revealed that
ABCF2 was highly expressed in advanced stages of NBL (p

1.9e-03).
Antigen Ki67 is a nuclear protein that is strictly associated
with, and might be necessary for, cellular proliferation. It was
recently reported that Ki67 might be suitable for inclusion in
the routine clinical screening of breast cancer (66). Ki67 was
found to be overexpressed in NBL tissues relative to normal
adrenal glands (p 
 9.0e-11), as shown in Fig. 5A. Interest-
ingly, in an NBL cohort, patients with loss of heterozygosity
for the chromosomal region 1p36 had high expression of Ki67
relative to patients without this deletion (supplemental Fig.
S5C) (p 
 2.4e-03). These findings further support the notion
that Ki67 is regulated by miR-34a.
We additionally found TIMM13, which encodes a member
of the “small Tim protein” family. Together with Tim8, Timm13
forms a soluble hexameric 70-kDa complex that is present in
the intermembrane space of mitochondria (67). This complex
is involved in the import of a number of inner membrane
proteins. Timm13 is a translocase involved in the import of
metabolite transporters from the cytoplasm into the mito-
chondrial inner membrane.
Finally, we identified ALG13, the subunit of a bipartite UDP-
N-acetylglucosamine transferase. It heterodimerizes with as-
paragine-linked glycosylation 14 homolog to form a functional
UDP-GlcNAc glycosyltransferase that catalyzes the second
sugar addition of the highly conserved oligosaccharide pre-
cursor in endoplasmic reticulum N-linked glycosylation. Along
with Ki67, Alg13 is highly expressed in patients with 1p36 loss
(p 
 1.1e-03) (supplemental Fig. S5C) in tumors where there
is a loss of the miR-34a genetic locus.
Further, several of these new miR-34a targets, LYAR,
CTCF, TGM2, Ki67, and TIMM13, are predicted to be linked to
one another and converge on important pathways that are
involved in tumor progression, such as the Wnt, TGF-, FAK,
and MAPK pathways (Fig. 6).
Canonical Wnt signaling controls events ranging from cell
fate determination and cell cycle regulation to cell motility and
metabolism. In addition to the importance of the canonical
Wnt pathway in normal cell function, pathologic increases in
Wnt signaling are frequently implicated in neoplastic states.
The importance of Wnt signaling in human cancer is high-
lighted by its coordinate control of the transcriptional pro-
grams underlying epithelial mesenchymal transition, cancer
stem cell generation, and cancer progression. WNT1 has
previously been report to be a direct target of miR-34a (68),
supporting the present demonstration that miR-34a sup-
pressed oncogenic Wnt signaling.
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We also found alterations to TGF- signaling, which is
already known to be involved in signaling that controls a wide
range of cellular processes, including cell proliferation, recog-
nition, differentiation, and apoptosis, and the specification of
developmental fate during embryogenesis and in mature tis-
sues in species ranging from flies and worms to mammals (45,
69, 70). TGF- suppresses early-stage tumor development
through its potent growth-inhibitory effects, but it is also a
pro-oncogenic factor that stimulates tumor cell growth and
invasiveness at later stages of tumorigenesis (71, 72). Patho-
logical forms of TGF- signaling promote tumor growth and
invasion, evasion of immune surveillance, and cancer-cell
dissemination and metastasis. Moreover, a recent study dem-
onstrated that miR-34a can target genes encoding multiple
TGF- isoforms (34). The inhibition of these pathways by
miR-34a has been confirmed in the literature and by data
obtained in our laboratory (73, 74).
An additional key finding is the alteration identified at early
times of pre-miR-34a expression for FAK, which is an impor-
tant mediator of growth factor signaling and cell proliferation,
survival, and migration. In the cancer context, the synergistic
signaling between growth factor receptors and FAK might be
particularly relevant in the control of the altered growth of
tumor cells, as well as in their responses to autocrine and
paracrine factors. In addition, through diverse molecular in-
teractions, FAK influences the dynamic regulation of integrin-
associated adhesions and the actin cytoskeleton, which is
tethered at the trailing edge (75). One potential question
raised at this time is how to explain why not all targets were
similarly down-regulated in the two NBL cellular models. Two
explanations can be offered; the first is intrinsic biological cell
differences and the second is the limitation of the proteomics
technique. Also, we should take into consideration the fact
that the reproducibility of sampling is not always 100% in all
the experiments performed (due to “undersampling”). Another
possibility would be related to different levels of target and
protein half-life in the two cell lines used. Additionally, by
comparing data from several proteomic analyses using the
overexpression of miR-34a, we were able to observe a list of
similar down-regulated targets and, most important, other
new targets were identified that seemed to be specific to
those cellular models analyzed (see supplemental Table S6).
Another important corollary of our proteome analysis is the
demonstration that the miR-34a effects on the proteome oc-
cur at early times. In vitro studies have already shown that
miRNAs can induce translational inhibition in a very short time
frame (76). Therefore, the effects of miR-34a on the proteome
were investigated in a time-dependent manner. Our data
demonstrated that pre-miR-34a expression resulted in protein
changes already observed at 6 h of expression. We found 20
and 56 down-regulated proteins in the SHEP-D and SH-
SY5Y-4 clones, respectively. Some of these proteins have
seed sequence sites in the 3-UTRs of their transcripts, which
could explain why these early down-regulation processes are
occurring upon miR34a expression.
There were also a number of repressed proteins that did not
show seed sequence sites. This implies that these proteins
are probably indirect targets of miR-34a or could be subject to
secondary effects that follow the direct miR-34a-mediated
repression of other proteins that act upstream, which in turn
regulate their expression.
Another explanation for this phenomenon might be that
they are indirectly regulated by miR-34a and because of their
short half-life we observed their down-regulation in a short
time frame. It is also worth noting that our data further show
the kinetics of miR-34a regulation. Here we analyzed the
effects of miR-34a on the proteome in a time-dependent
manner, allowing us to obtain a global picture of the miR-34a
functions.
Recently, in vivo studies showed that tumor growth is sig-
nificantly repressed after exogenous miR-34a administration
in retroperitoneal NBL tumors (39). Identification of miR-34a is
a highly significant finding with respect to the development of
potential therapeutics for NBL. Current therapies for high-risk
NBL include chemotherapy and radiotherapy, which attempt
to hinder tumor relapse.
The emerging data from the present study provide a unify-
ing principle that will lead to improvements in cancer therapy
using ectopic miR-34a expression, which might also serve as
a tumor therapeutic for human tumors in the future. Compre-
hensive knowledge of the targets and effects of miR-34a is
also of relevance to the evaluation of the potential side effects
of such therapies.
CONCLUSIONS
The role of miRNAs in mediating critical cellular processes
is an emerging field in cancer genetics. Dysregulation, en-
hanced expression, and selective inhibition of miRNAs have
improved the scientific understanding of the functional roles
of these regulatory molecules in determining cancer progres-
sion and patient prognosis. MiR-34a was the first miRNA
identified as a putative tumor suppressor in NBL, through its
direct targeting of transcription factors and other genes es-
sential for cell proliferation. Here, we have identified new early
targets of miR-34a, adding an important step to our under-
standing of the mechanisms of action of miR-34a. Although
miRNAs are largely known to repressively regulate protein
expression, it has been reported that some miRNAs can also
up-regulate translation (77). In the present study, we focused
on the repressive gene regulation of miR-34a as a result of its
binding to the 3-UTR of target genes, although many up-
regulated proteins have also been detected in quantitative
bottom-up proteomics analysis. These data were further con-
firmed by wet-bench analyses of effects in the cell context, as
related to cell proliferation, apoptosis, and the initiation of
cellular adhesion processes. Further studies will be needed to
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determine mechanistically how miR-34a can up-regulate
some proteins.
In conclusion, in the present study, our efforts were ori-
ented toward not only the identification of new targets of
miR-34a in NBL, but also the molecular principles that govern
early events in the kinetics of gene regulation by miRNAs.
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